(Q54566271)

1 June 2018

title

Correlation analysis of p53 protein isoforms with NPM1/FLT3 mutations and therapy response in acute myeloid leukemia. (English)

1 reference

1 June 2018

1 reference

10

P E Lønning

1 reference

1 June 2018

9

S Knappskog

1 reference

1 June 2018

12

B T Gjertsen

1 reference

1 June 2018

8

K Taskén

1 reference

1 June 2018

N Ånensen

1

1 reference

1 June 2018

S M Hjelle

2

1 reference

1 June 2018

W Van Belle

3

1 reference

1 June 2018

I Haaland

4

1 reference

1 June 2018

E Silden

5

1 reference

1 June 2018

J-C Bourdon

6

1 reference

1 June 2018

R Hovland

7

1 reference

1 June 2018

Ø Bruserud

11

1 reference

1 June 2018

language of work or name

English

0 references

publication date

22 August 2011

1 reference

1 June 2018

published in

Oncogene

1 reference

1 June 2018

volume

31

1 reference

1 June 2018

issue

12

1 reference

1 June 2018

page(s)

1533-1545

1 reference

1 June 2018

https://scigraph.springernature.com/pub.10.1038/onc.2011.348

exact match

0 references

cites work

p53 isoforms can regulate p53 transcriptional activity.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.348

p53 mutant breast cancer patients expressing p53γ have as good a prognosis as wild-type p53 breast cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.348

p53 isoform delta113p53 is a p53 target gene that antagonizes p53 apoptotic activity via BclxL activation in zebrafish.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.348

CHEK2 mutations affecting kinase activity together with mutations in TP53 indicate a functional pathway associated with resistance to epirubicin in primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.348

Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.348

21 January 2018

Acute myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.348

Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.348

Control of apoptosis by p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.348

p53 isoforms Delta133p53 and p53beta are endogenous regulators of replicative cellular senescence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.348

No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients, excluding acute promyelocytic leukemia, from the UK MRC AML10 and 12 trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.348

Analysis of acute myelogenous leukemia: preparation of samples for genomic and proteomic analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.348

Functional characterization of p53beta and p53gamma, two isoforms of the tumor suppressor p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.348

21 January 2018

Nucleophosmin and cancer

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.348

Assessing p53 in clinical contexts: unlearned lessons and new perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.348

Single cell profiling of potentiated phospho-protein networks in cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.348

Inactivation of Smad4 accelerates Kras(G12D)-mediated pancreatic neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.348

Identification of Ki23819, a highly potent inhibitor of kinase activity of mutant FLT3 receptor tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.348

The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the Unite

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.348

p53, the cellular gatekeeper for growth and division

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.348

The first 30 years of p53: growing ever more complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.348

Study of suboptimum treatment response: lessons from breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.348

21 January 2018

Acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.348

Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.348

Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.348

Flt3-ITD alters chemotherapy response in vitro and in vivo in a p53-dependent manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.348

An integrated genomic analysis of human glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.348

TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.348

The clinical significance of mutations of the P53 tumour suppressor gene in haematological malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.348

A novel human p53 isoform is an essential element of the ATR-intra-S phase checkpoint

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.348

Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.348

Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.348

Extracellular signal-regulated kinase and p38 mitogen-activated protein kinase pathways cooperate in mediating cytokine-induced proliferation of a leukemic cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.348

Drug therapy for acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.348

Correlation analysis of two-dimensional gel electrophoretic protein patterns and biological variables

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.348

Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.348

p53 in health and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.348

A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.348

Phosphorylation of p53 on Thr55 by ERK2 is necessary for doxorubicin-induced p53 activation and cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.348

Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.348

A distinct p53 protein isoform signature reflects the onset of induction chemotherapy for acute myeloid leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.348

Mutations of the P53 gene in acute myeloid leukaemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.348

Relationship between FLT3 mutation status, biologic characteristics, and response to targeted therapy in acute promyelocytic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.348

Mutations of the TP53 gene in acute myeloid leukemia are strongly associated with a complex aberrant karyotype

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.348

Flt3 Y591 duplication and Bcl-2 overexpression are detected in acute myeloid leukemia cells with high levels of phosphorylated wild-type p53

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.348

Acute myeloid leukemia: the challenge of capturing disease variety

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.348

Outcome of a multicenter treatment program including autologous or allogeneic bone marrow transplantation for de novo acute myeloid leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.348

31 March 2020

Identifiers

DOI

10.1038/ONC.2011.348

1 reference

1 June 2018

PubMed ID

21860418

1 reference

1 June 2018